CompletedPhase 2NCT02760277
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Studying Duchenne muscular dystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ReveraGen BioPharma, Inc.
- Principal Investigator
- Paula R Clemens, MDUniversity of Pittsburgh
- Intervention
- Vamorolone 0.25 mg/day/day(drug)
- Enrollment
- 48 enrolled
- Eligibility
- 4-7 years · MALE
- Timeline
- 2016 – 2018
Study locations (12)
- University of California Davis, Davis, California, United States
- University of Florida, Gainesville, Florida, United States
- Nemours Children's Hospital, Orlando, Florida, United States
- Ann & Robert H. Lurie Children's Hospital, Chicago, Illinois, United States
- Duke University, Durham, North Carolina, United States
- University of Texas Southwestern Medical Center, Dallas, Texas, United States
- Royal Children's Hospital, Melbourne, Australia
- Sydney Children's Hospital, Westmead, Australia
- Alberta Children's Hospital, Calgary, Alberta, Canada
- Schneider Children's Medical Center, Petah Tikva, Israel
- Queen Silvia Children's Hospital, Gothenburg, Sweden
- Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
Collaborators
University of Pittsburgh · National Institute of Neurological Disorders and Stroke (NINDS) · Cooperative International Neuromuscular Research Group · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02760277 on ClinicalTrials.govOther trials for Duchenne muscular dystrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07332013Urinary Titin Biomarker in DMDChildren's Hospital of Philadelphia
- RECRUITINGNCT07092540The Baby Duchenne Study: Characterizing Developmental and Clinical Outcomes in the First Three Years in Children With Duchenne Muscular DystrophyUniversity of Rochester
- ENROLLING BY INVITATIONNANCT06887491The Effect of Dual-tasking Program on Cognitive and Physical Functions and Independence in Activities of Daily Living in Children With Duchenne Muscular Dystrophy: A Single-blind Randomized Controlled TrialLokman Hekim University
- ACTIVE NOT RECRUITINGPHASE1NCT07347548A Trial to Investigate the Safety and Pharmacokinetics of GRT6019 in Healthy Male ParticipantsGrünenthal GmbH
- ENROLLING BY INVITATIONPHASE2NCT07209332Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular DystrophyWave Life Sciences Ltd.
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT07282652A Study to Evaluate the Safety and Tolerability of RAG-18 in Pediatric Patients With Duchenne Muscular DystrophyPeking Union Medical College Hospital
- RECRUITINGPHASE2NCT07287189Phase 2 Study of SAT-3247 in Pediatric Ambulatory PatientsSatellos Bioscience, Inc.
- ENROLLING BY INVITATIONNCT07435116Duchenne Muscular Dystrophy and the Viscoelastic Properties of Upper Limb MusclesSanko University